CTRI/2018/10/015921已完成未知
An open label, multicenter, randomized, balanced, two-treatment, two-period, two-sequence, single-dose, crossover, oral bioequivalence study of Methotrexate Tablets, USP 2.5mg from Lotus Pharmaceutical Co., Ltd., Taiwan compared with that of Methotrexate Tablets, USP 2.5 mg manufactured for DAVA Pharmaceuticals, Inc., in adult patients with mild to severe psoriasis or rheumatoid arthritis under fasting conditions.
otus Pharmaceutical Co Ltd0 个研究点目标入组 50 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Patients with mild to severe psoriasis or rheumatoid arthritis and are already on established regimens of Methotrexate tablets 2.5 mg at 12 hour intervals for 3 doses given as a course once weekly.
- •2. Patients aged 18 to 65 years at the time of screening.
- •3. Patients who voluntarily agree to participate in the study and give their informed consent.
- •4. Patients who agree to comply with study procedures and the schedule of clinical and follow-up visit.
- •5. Patients who agree to comply with study specific restrictions and prohibitions.
- •6. Normal or clinically acceptable findings during screening, medical history, medical examination, laboratory evaluations (Haemoglobin value more than or equal to 10 g/dL), 12 lead ECG and X-ray chestpostero-anterior view recordings.
- •7. Female patients of childbearing potential (excluding women who are surgically sterilized or postmenopausal for at least 2 years), in additionto having a negative urine pregnancy test, must be willing to use an acceptable form of birth control during the study.
排除标准
- •1. Patients with known hypersensitivity or idiosyncratic reaction to the study drug or any related drug.
- •2. Patients with history of allergic reaction to heparin.
- •3. Patients who had a significant surgery within 2 weeks prior to enrolling in study and as per the investigator, their inclusion may affect the
- •objective of the study.
- •4. Patients with any uncontrolled medical problem e.g. heart, lung disease or clinically significant abnormal laboratory values that in the opinion
- •of the investigator would preclude safe administration of the study drug.
- •5. Patients with clinically unacceptable abnormal laboratory values during screening.
- •6. Patients with history or presence gastrointestinal ulceration, bleeding and/or perforation.
- •7. Patients with preexisting blood dyscrasias, such as bone marrow hypoplasia, leukopenia, thrombocytopenia or significant anemia.
- •8. Patients with overt or laboratory evidence of immunodeficiency syndromes.
- •9. Patients with history or presence of any disease or disorder known to influence bone metabolism, compromise the hemopoietic, renal,
- •hepatic, endocrine, pulmonary, central nervous, cardiovascular, gastrointestinal or any other body system.
- •10. Patients with any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAID induced urticaria.
- •11. Patients with kidney dysfunction/renal impairment.
- •12. Patients with ascites and pleural effusion.
- •13. Patients with history or presence of cancer.
- •14. Patients with Coagulation disorders.
- •15. Patients with uncontrolled diabetes mellitus and hypertension.
- •16. Patient with recent history of alcoholism ( <2 years) or daily consumption of alcohol or alcoholic products, alcoholic liver disease or
- •other chronic liver disease.
- •17. Patients who are current smokers, who smoke 10 or more cigarettes/day.
- •18. Patients with history of current or previous use of any recreational drugs or history of drug addiction.
- •19. Patients with history of difficulty with donating blood or having donated blood in the preceding 90 days prior to the start of the study.
- •20. Patient who has participated in any other clinical study involving drug administration and collection of blood samples in the 90 days preceding the start of the study.
- •21. Patients with difficulty in swallowing capsule/tablet.
- •22. Patients who are positive for HIV, VDRL/RPR, Hepatitis B and C tests.
- •23. Female patients demonstrating a positive pregnancy screen or currently breast-feeding.
研究者
相似试验
进行中（未招募）
不适用
A study of Capecitabine 200 mg/ ml with Xeloda 500 mg (Capecitabine) at a dose of 2000 mg in adult human cancer patients under fed conditions.CTRI/2020/10/028417Shilpa Medicare Limited
进行中（未招募）
Unknown
euprolide acetate in the treatment of Prostate Cancer.CTRI/2023/09/057619Pharmathen S.A.
已完成
不适用
Imatinib Mesylate Oral Solution 400mg/5ml with Gleevec® (Imatinib mesylate) Tablets 400mg in adult human subjects with Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumors under fed condition.CTRI/2020/03/024404Shilpa Medicare Limited35
已完成
不适用
Open label multicenter randomized parallel single-period single dose bio equivalence study of Leuprolide acetate 30 mg in adult male subjects with advanced prostaticcancer undergoing initial therapy.CTRI/2020/10/028442Pharmathen SA32
已完成
不适用
To evaluate bioavailability of oral Capecitabine in adult human cancer patients under fed conditionsCTRI/2021/06/034321ShilpaMedicareLimited35